GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genus PLC (OTCPK:GENSF) » Definitions » Short Interest

Genus (GENSF) Short Interest


View and export this data going back to . Start your Free Trial

What is Genus Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Genus's Short Interest

For the Biotechnology subindustry, Genus's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genus's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genus's Short Interest distribution charts can be found below:

* The bar in red indicates where Genus's Short Interest falls into.



Genus (GENSF) Business Description

Traded in Other Exchanges
Address
Matrix House, Basing View, Basingstoke, Hants, GBR, RG21 4DZ
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB.